Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Swindells

Showing results (111-120 of 170) with videos related to

Pageof 17
Sort By:
American Journal of Respiratory and Critical Care Medicine|January 17, 2020
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical TrialKelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine|March 5, 2020
Reply to Decroo <i>et al.</i>: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible TuberculosisKelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
Brain, Behavior, and Immunity|October 22, 2022
Mitochondrial redox environments predict sensorimotor brain-behavior dynamics in adults with HIVRachel K Spooner, Brittany K Taylor, Iman M Ahmad, et al.
Hepatology (Baltimore, Md.)|October 24, 2006
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters, Janet Andersen, Patrick Lynch, et al.
The Patient|May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.
AIDS and Behavior|May 16, 2020
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 TrialsAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
Journal of Neuroimmunology|May 12, 2005
Development of a rapid autopsy program for studies of brain immunityAnuja Ghorpade, Leslie Bruch, Yuri Persidsky, et al.
The Journal of Infectious Diseases|July 20, 2012
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted miceUpal Roy, JoEllyn McMillan, Yazen Alnouti, et al.
Pharmacogenetics and Genomics|February 17, 2025
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosisNia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, et al.
Molecular Cell|April 23, 2016
Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLAAndrew M Gross, Philipp A Jaeger, Jason F Kreisberg, et al.
Pageof 17

Showing results (111-120 of 170) with videos related to

Sort By:
Pageof 17
American Journal of Respiratory and Critical Care Medicine|January 17, 2020
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical TrialKelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine|March 5, 2020
Reply to Decroo <i>et al.</i>: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible TuberculosisKelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
Brain, Behavior, and Immunity|October 22, 2022
Mitochondrial redox environments predict sensorimotor brain-behavior dynamics in adults with HIVRachel K Spooner, Brittany K Taylor, Iman M Ahmad, et al.
Hepatology (Baltimore, Md.)|October 24, 2006
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters, Janet Andersen, Patrick Lynch, et al.
The Patient|May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.
AIDS and Behavior|May 16, 2020
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 TrialsAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
Journal of Neuroimmunology|May 12, 2005
Development of a rapid autopsy program for studies of brain immunityAnuja Ghorpade, Leslie Bruch, Yuri Persidsky, et al.
The Journal of Infectious Diseases|July 20, 2012
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted miceUpal Roy, JoEllyn McMillan, Yazen Alnouti, et al.
Pharmacogenetics and Genomics|February 17, 2025
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosisNia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, et al.
Molecular Cell|April 23, 2016
Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLAAndrew M Gross, Philipp A Jaeger, Jason F Kreisberg, et al.
Pageof 17